Sanofi (NASDAQ:SNY) Upgraded at StockNews.com

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a research note published on Friday morning.

Several other brokerages also recently weighed in on SNY. Citigroup raised Sanofi to a strong-buy rating in a research note on Tuesday, September 17th. Argus lifted their target price on Sanofi from $55.00 to $60.00 and gave the company a buy rating in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi has a consensus rating of Moderate Buy and an average target price of $57.50.

Sanofi Trading Down 1.1 %

NASDAQ:SNY opened at $57.63 on Friday. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The firm has a market capitalization of $145.96 billion, a P/E ratio of 28.96, a P/E/G ratio of 1.62 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The business has a 50 day simple moving average of $54.34 and a 200 day simple moving average of $50.50.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. During the same quarter in the previous year, the firm posted $0.95 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. Equities research analysts predict that Sanofi will post 4.25 EPS for the current year.

Institutional Trading of Sanofi

A number of hedge funds and other institutional investors have recently modified their holdings of the company. TCTC Holdings LLC raised its stake in shares of Sanofi by 28.0% in the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock worth $47,000 after buying an additional 210 shares in the last quarter. HB Wealth Management LLC raised its position in shares of Sanofi by 3.7% during the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock worth $299,000 after purchasing an additional 221 shares during the period. Wynn Capital LLC lifted its holdings in shares of Sanofi by 4.5% during the first quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock valued at $256,000 after purchasing an additional 226 shares during the last quarter. Insigneo Advisory Services LLC lifted its holdings in shares of Sanofi by 3.3% during the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock valued at $371,000 after purchasing an additional 228 shares during the last quarter. Finally, Angeles Investment Advisors LLC lifted its holdings in shares of Sanofi by 2.1% during the fourth quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company’s stock valued at $598,000 after purchasing an additional 244 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.